Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.4069
-0.0467 (-10.30%)
Nov 16, 2026, 4:00 PM EST - Market closed
Kairos Pharma Employees
As of December 31, 2025, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees. The number of employees did not change compared to the previous year. That makes Kairos Pharma the 42,328th largest employer in the world and 6,621st in the United States.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,597,750
Market Cap
1.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 1 | 3 |
| Dec 31, 2024 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Enlivex | 34 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| Curis | 24 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| 60 Degrees Pharmaceuticals | 3 |
KAPA News
- 3 days ago - Kairos Pharma Quarterly report: Q3 2026 - Filings
- 11 days ago - Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology - Business Wire
- 13 days ago - Kairos Pharma Presents at United Scientific Group's 11th International Conference on Cancer Research & Drug Development - Business Wire
- 25 days ago - CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma - Newsfile Corp
- 27 days ago - Kairos Pharma Transcript: LD Micro 20th Annual Main Event Conference - Transcripts
- 5 weeks ago - Kairos Pharma announces interim efficacy data from Phase 2 trial of ENV-105 - TheFly
- 5 weeks ago - Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer - Business Wire
- 7 weeks ago - Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA - Business Wire